MASH CLINICAL
MASH Clinical comprises a global network of clinicians, investigators and experts in the MASH (Formerly known as NASH) field. Emphasizing the importance of the Patients Care Path, a firm collaboration is set up with the participating clinicians, involving Primary Care Physicians, Endocrinologists, Diabetologists, Hepatologists and Gastroenterologists. MASH Clinical aims to share insights about this endemic disease, to collaboratively create easy-and-accurate diagnostic tools to identify these patients, and to conduct clinical trials to mitigate the potentially deleterious outcome of this disease.
DAshboard | interactive map of oUR GLOBAL REACH and experience
mash CLinical webinar series
This webinar is the 12th of the MASH webinar series, each focusing on recent developments or publications on Metabolic dysfunction-associated steatohepatitis (MASH). The topics and publications are selected by KOLs of MASH Clinical based on relevant ground-breaking MASH research in a high-impact journal. During these webinars we offer you the opportunity to interact with original authors and experts in the MASH field.
MASH CLinical video
Every now and then an article on MASH is published which is relevant for both clinicians and scientists. "Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum", by Cheung et al* is such an article. When can we speak of a real improvement due to treatment in MASH patients? If you happen to have 5 minutes left, have a look at this MASH Clinical video! We think it is worthwhile.
* Journal of the American College of Cardiology.
2019 By the American College of Cardiolofy Foundation - Published by Elsavier.
* Journal of the American College of Cardiology.
2019 By the American College of Cardiolofy Foundation - Published by Elsavier.
| defining_improvement_in_nonalcoholic_steatohepatitis |
WHAT IS MASH?
|
MASH is an acronym that stands for Metabolic dysfunction-associated steatohepatitis. It is the most severe form of metabolic dysfunction-associated steatotic liver disease (MASLD), and is characterized by the presence of an abnormal accumulation of fat in the liver which in some individuals can progress to liver cell injury (hepatocellular ballooning) and inflammation. As MASH evolves, over time it can result in excessive scarring in the liver (fibrosis), a natural response to injury which can lead to liver cirrhosis or liver cancer.
MASLD is often associated with insulin resistance and is strongly associated with type 2 diabetes mellitus and obesity. In addition to being at risk for MASH, cirrhosis and its complications, MASLD patients are also at higher risk of cardiovascular diseases (CVD), including coronary heart disease and stroke. MASLD confers increased cardiovascular disease risk independent of traditional cardiovascular risk factors and metabolic syndrome. Individuals with MASH, have a high frequency of metabolic co-morbidities and could place a growing strain on health-care systems from their need for management. While awaiting the development effective therapies, this disease warrants the attention of primary care physicians, specialists and health policy makers. |
Bron: The NASH education program
|
lifestyle disease
MASH is closely related to the epidemic of obesity, pre-diabetes, and diabetes, and can be defined as the liver manifestation of the metabolic syndrome. It is heavily influenced by lifestyle (e.g. chronic excessive calorie intake, sedentary activity) and is distinct from other fatty liver diseases caused by alcohol abuse or medication side effects
Nowadays MASH is the 2nd most common indication for liver transplantation in the USA. The ongoing obesity epidemic makes MASH a serious burden of disease. So, there is an urgent need for effective drugs.
Nowadays MASH is the 2nd most common indication for liver transplantation in the USA. The ongoing obesity epidemic makes MASH a serious burden of disease. So, there is an urgent need for effective drugs.
WHY MASH CLINICAL?
Interdisciplinary collaboration is needed to combat MASH and consequently we have created MASH clinical network. The aim of this network is to share insights about this endemic disease, to collaboratively create easy-and-accurate diagnostic tools to identify these patients, and to conduct clinical trials to mitigate the potentially deleterious outcome of this disease.